Seprehvir (HSV1716) is an oncolytic herpes simplex virus-1 (HSV-1) previously demonstrated to be well tolerated in pediatric patients when administered intratumorally. To determine the safety of administering Seprehvir systemically, we conducted the first-in-human phase I trial of intravenous injection in young patients with relapsed or refractory extra-cranial solid cancers. We delivered a single dose of 5 × 104 infectious units (iu)/kg (maximum dose of 2 × 106) or 2.5 × 105 iu/kg (maximum dose of 1 × 107 iu) of Seprehvir via the peripheral vein, monitored adverse events, and measured tumor responses by imaging. We monitored HSV-1 serology as well as viremia and shedding by PCR and culture. We administered a single dose of Seprehvir to seven patients and multiple doses to two patients. We did not observe any dose-limiting toxicities. All five HSV-1 seronegative patients seroconverted by day 28. Four of nine patients had detectable HSV-1 genomes in peripheral blood appearing on day +4 consistent with de novo virus replication. Two patients had stable disease in response to Seprehvir. Intravenous Seprehvir is well tolerated without viral shedding in children and young adults with late-stage cancer. Viremia consistent with virus replication holds promise for future Seprehvir studies at higher doses and/or in combination with other anti-neoplastic therapies.
PURPOSE: Although chemoimmunotherapy is widely used for treatment of children with relapsed high-risk neuroblastoma (HRNB), little is known about timing, duration, and evolution of response after irinotecan/temozolomide/dinutuximab/granulocyte-macrophage colony-stimulating factor (I/T/DIN/GM-CSF) therapy. PATIENTS AND METHODS: Patients eligible for this retrospective study were age < 30 years at diagnosis of HRNB and received ≥ 1 cycle of I/T/DIN/GM-CSF for relapsed or progressive disease. Patients with primary refractory disease who progressed through induction were excluded. Responses were evaluated using the International Neuroblastoma Response Criteria. RESULTS: One hundred forty-six patients were included. Tumors were MYCN-amplified in 50 of 134 (37%). Seventy-one patients (49%) had an objective response to I/T/DIN/GM-CSF (objective response; 29% complete response, 14% partial response [PR], 5% minor response [MR], 21% stable disease [SD], and 30% progressive disease). Of patients with SD or better at first post-I/T/DIN/GM-CSF disease evaluation, 22% had an improved response per International Neuroblastoma Response Criteria on subsequent evaluation (13% of patients with initial SD, 33% with MR, and 41% with PR). Patients received a median of 4.5 (range, 1-31) cycles. The median progression-free survival (PFS) was 13.1 months, and the 1-year PFS and 2-year PFS were 50% and 28%, respectively. The median duration of response was 15.9 months; the median PFS off all anticancer therapy was 10.4 months after discontinuation of I/T/DIN/GM-CSF. CONCLUSION: Approximately half of patients receiving I/T/DIN/GM-CSF for relapsed HRNB had objective responses. Patients with initial SD were unlikely to have an objective response, but > 1 of 3 patients with MR/PR on first evaluation ultimately had complete response. I/T/DIN/GM-CSF was associated with extended PFS in responders both during and after discontinuation of treatment. This study establishes a new comparator for response and survival in patients with relapsed HRNB.
Background: Diagnostic mIBG (meta‐iodobenzylguanidine) scans are an integral component of response assessment in children with high‐risk neuroblastoma. The role of end‐of‐induction (EOI) Curie scores (CS) was previously described in patients undergoing a single course of high‐dose chemotherapy (HDC) and autologous hematopoietic cell transplant (AHCT) as consolidation therapy.Objective: We now examine the prognostic significance of CS in patients randomized to tandem HDC and AHCT on the Children's Oncology Group (COG) trial ANBL0532.Study design: A retrospective analysis of mIBG scans obtained from patients enrolled in COG ANBL0532 was performed. Evaluable patients had mIBG‐avid, International Neuroblastoma Staging System (INSS) stage 4 disease, did not progress during induction therapy, consented to consolidation randomization, and received either single or tandem HDC (n = 80). Optimal CS cut points maximized the outcome difference (≤CS vs. >CS cut‐off) according to the Youden index.Results: For recipients of tandem HDC, the optimal cut point at diagnosis was CS = 12, with superior event‐free survival (EFS) from study enrollment for patients with CS ≤ 12 (3‐year EFS 74.2% ± 7.9%) versus CS > 12 (59.2% ± 7.1%) (p = .002). At EOI, the optimal cut point was CS = 0, with superior EOI EFS for patients with CS = 0 (72.9% ± 6.4%) versus CS > 0 (46.5% ± 9.1%) (p = .002).Conclusion: In the setting of tandem transplantation for children with high‐risk neuroblastoma, CS at diagnosis and EOI may identify a more favorable patient group. Patients treated with tandem HDC who exhibited a CS ≤ 12 at diagnosis or CS = 0 at EOI had superior EFS compared to those with CS above these cut points.
1 December 2011 in Journal of Adolescent and Young Adult Oncology
Purpose: To review a single institution's experience with rhabdomyosarcoma (RMS) in the adolescent and young adult (AYA) age group as compared to younger patients with RMS in regard to patient characteristics at diagnosis, treatment outcome, and treatment toxicities. Patients and Methods: A retrospective 25-year review was conducted of all patients diagnosed with RMS who received treatment at Nationwide Children's Hospital between 1984 and 2008. Data were collected on patient characteristics at diagnosis, including vital status, histology, primary tumor location, metastatic status, modalities of treatment, and toxicities of therapy. Results: Twenty-one AYAs (aged 15–25 at diagnosis) were treated at Nationwide Children's Hospital in the 25-year time period, compared to 72 patients less than 15 years of age. Of these, currently 63.6% of patients aged 15 or older have died of their disease compared to only 33.7% of those aged 14 or younger. Higher percentages of alveolar histology, unfavorable location of primary tumor, and distant metastases were noted in the AYA patients. The percentage of AYA patients experiencing delays in chemotherapy or vincristine toxicity was not significantly different from that in younger patients. Conclusion: At our institution, survival for AYA patients with RMS was poor compared to younger children. In this cohort, the survival difference appears to be a function of a higher percentage of patients with unfavorable disease characteristics, rather than difficulty tolerating chemotherapy. Further study is necessary to define the biology and characteristics of RMS better in this population.
15 November 2025 in Transplantation and Cellular Therapy